Cilostazol (Pletal®): A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake

Cardiovascular Drug Reviews

Volumn 19, Issue 4, 2001, Pages 369-386

  Liu, Yongge ^a   Shakur, Yasmin ^a   Yoshitake, Masuhiro ^a   Kambayashi, Jun Ichi ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Adenosine uptake; Cilostazol; Intermittent claudication; PDE3; Peripheral arterial disease; Platelet aggregation; Pletal ; Vasodilation

Indexed keywords

ADENOSINE; CILOSTAZOL; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; DEHYDROCILOSTAZOL; ERYTHROMYCIN; MEVINOLIN; MILRINONE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; WARFARIN; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CYCLIC AMP; FIBRINOLYTIC AGENT; PHOSPHODIESTERASE III; TETRAZOLE DERIVATIVE; VASODILATOR AGENT;

CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; INTERMITTENT CLAUDICATION; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; STROKE; VERTIGO; ANIMAL; CELL DIVISION; CEREBROVASCULAR ACCIDENT; CHEMISTRY; CYTOLOGY; DRUG ANTAGONISM; METABOLISM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADENOSINE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ANTILIPEMIC AGENTS; ARTERIAL OCCLUSIVE DISEASES; CELL DIVISION; CEREBROVASCULAR ACCIDENT; CORONARY RESTENOSIS; CORONARY THROMBOSIS; CYCLIC AMP; FIBRINOLYTIC AGENTS; HUMANS; MUSCLE, SMOOTH, VASCULAR; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; TETRAZOLES; VASODILATOR AGENTS;

EID: 0035544829     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2001.tb00076.x     Document Type: Review

References (84)

1. Multiple cyclic nucleotide phosphodiesterases
2. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial
3. Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers
4. Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol
5. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells
6. Cyclic GMP phosphodiesterase-5: Target of sildenafil
7. Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus
8. A comparison of cilostazol and pentoxifylline for treating intermittent claudication
9. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial
10. The effect of withdrawal of drugs treating intermittent claudication
11. Cellular mechanisms in ischemic preconditioning: The role of adenosine and protein kinase C
12. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication
13. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A
14. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction
15. Cyclic nucleotides and phosphodiesterases in platelets
16. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients
17. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21
18. Current and future drug therapies for claudication
19. Medical treatment of peripheral arterial disease and claudication
20. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells
21. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor
22. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study
23. Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery
24. Effect of cilostazol, a new antithrombotic drug, on cerebral circulation
25. The effect of cilostazol, a cyclic nucleotide phosphodiesterase III inhibitor, on heparin-binding EGF-like growth factor expression in macrophages and vascular smooth muscle cells
26. Selective type III phosphodiesterase inhibitor as an antithrombotic agent
27. Effect of cilostazol on platelet aggregation and experimental thrombosis
28. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery
29. Differential sensitivity to cardiotonic drugs of cyclic AMP phosphodiesterases isolated from canine ventricular and sinoatrial-enriched tissues
30. Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation
31. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study
32. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation
33. Pharmacological preconditioning of ischaemia
34. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication
35. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication
36. Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin
37. Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites
38. Interaction potential and tolerability of the coadministration of cilostazol and aspirin
39. Comparative study of antiplatelet drugs in vitro: Distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses
40. Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation
41. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo
42. Evaluation of OPC-13013 in chronic arterial occlusion
43. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
44. Role of hepatocyte growth factor in endothelial regulation: Prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor
45. 1 receptor anti-adrenergic effect in rat cardiac myocytes
46. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells
47. Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction
48. Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen
49. Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion
50. Characterization of the uptake of adenosine by cultured rat hippocampal cells and inhibition of the uptake by xanthine derivatives
51. Cilostazol
52. Treatment of chronic heart failure
53. Effect of oral milrinone on mortality in severe chronic heart failure
54. Comparison of cilostazol versus ticlopidine therapy after stent implantation
55. Adenosine and chronic ischemia of the lower limbs
56. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation
57. Aggregation of human blood platelets by remnant like lipoprotein particles of plasma chylomicrons and very low density lipoproteins
58. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis
59. Comparison of the effects of cilostazol and milrinone on rabbit and human cardiac cAMP-PDE activity and on rabbit cardiac function
60. OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells
61. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity
62. Interplay between adenosine and cilostazol in antiplatelet activation
63. Effect of omeprazole on the metabolism of cilostazol
64. Effects of CYP3A inhibition on the metabolism of cilostazol
65. The adipocyte cGMP-inhibited cyclic nucleotide phosphodiesterase (PDE3B) as a target for liolytic and thermogenic agents for the treatment of obesity
66. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture
67. Effect of cilostazol on serum lipid levels in diabetic patients
68. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty
69. Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus
70. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle
71. Pharmacological manipulation of tissue cyclic AMP by inhibitors. Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells
72. Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats
73. FDA Panel report: January 1998
74. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty
75. Effects of cilostazol on platelet function
76. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro
77. Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication
78. Attenuation of vasospasm and capillary no-reflow by ischemic preconditioning in skeletal muscle
79. The effect of ischemic preconditioning on the recovery of skeletal muscle following tourniquet ischemia
80. Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation
81. Hemodynamic effect of cilostazol on increasing peripheral blood flow in arteriosclerosis obliterans
82. Clinical effects of oral cilostazol on suppression of platelet function in patients with cerebrovascular disease
83. Antiplatelet treatment with cilostazol after stent implantation